oxaliplatin-teva
teva pharmaceutical works private limited company - oxaliplatin - concentrate for solution for infusion - 5mg/ml
oxaliplatin-teva
teva pharmaceutical works private limited company - oxaliplatin - concentrate for solution for infusion - 5mg/ml
ondansetron-teva
teva pharmaceutical works private limited company - ondansetron (ondansetron hydrochloride dihydrate) - solution for injection - 2mg/ml
ondansetron-teva
teva pharmaceutical works private limited company - ondansetron (ondansetron hydrochloride dihydrate) - solution for injection - 2mg/ml
vanco-teva 1 gr
teva pharmaceutical industries ltd, israel - vancomycin as hydrochloride - lyophilized powder for injection - vancomycin as hydrochloride 1 g/vial - vancomycin - vancomycin - vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-iactam-resistant) staphylococci. it is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. antibiotic therapy is as an adjunct to appropriate surgical measures when sta
vanco-teva 500 mg
teva pharmaceutical industries ltd, israel - vancomycin as hydrochloride - lyophilized powder for injection - vancomycin as hydrochloride 500 mg/vial - vancomycin - vancomycin - vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-iactam-resistant) staphylococci. it is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. antibiotic therapy is as an adjunct to appropriate surgical measures when sta
tacrolimus–teva prolonged release hard capsule 0.5mg
teva pharmaceutical investments singapore pte. ltd. - tacrolimus monohydrate eqv tacrolimus - capsule, extended release - tacrolimus monohydrate eqv tacrolimus 0.5 mg
tacrolimus–teva prolonged release hard capsule 1mg
teva pharmaceutical investments singapore pte. ltd. - tacrolimus monohydrate eqv tacrolimus - capsule, extended release - tacrolimus monohydrate eqv tacrolimus 1.0 mg
tacrolimus–teva prolonged release hard capsule 5mg
teva pharmaceutical investments singapore pte. ltd. - tacrolimus monohydrate eqv tacrolimus - capsule, extended release - tacrolimus monohydrate eqv tacrolimus 5.0 mg
tamsulosin-teva prolonged release film-coated tablet 400mcg
teva pharmaceutical investments singapore pte. ltd. - tamsulosin eqv tamsulosin hydrochloride - tablet, film coated, extended release - tamsulosin eqv tamsulosin hydrochloride 0.40 mg